Head to Head Contrast: GenVec (GNVC) versus CTI BioPharma Corp. (CTIC)

GenVec (NASDAQ: GNVC) and CTI BioPharma Corp. (NASDAQ:CTIC) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, dividends, valuation and analyst recommendations.

Valuation and Earnings

This table compares GenVec and CTI BioPharma Corp.’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
GenVec N/A N/A N/A ($3.65) -1.97
CTI BioPharma Corp. $36.55 million 2.78 -$50.38 million ($1.91) -1.68

GenVec has higher revenue, but lower earnings than CTI BioPharma Corp.. GenVec is trading at a lower price-to-earnings ratio than CTI BioPharma Corp., indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations and price targets for GenVec and CTI BioPharma Corp., as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GenVec 0 2 0 0 2.00
CTI BioPharma Corp. 0 0 1 0 3.00

GenVec currently has a consensus price target of $7.00, indicating a potential downside of 2.68%. CTI BioPharma Corp. has a consensus price target of $7.50, indicating a potential upside of 134.38%. Given CTI BioPharma Corp.’s stronger consensus rating and higher possible upside, analysts clearly believe CTI BioPharma Corp. is more favorable than GenVec.

Profitability

This table compares GenVec and CTI BioPharma Corp.’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
GenVec -3,748.25% -648.22% -271.77%
CTI BioPharma Corp. -136.76% -418.99% -73.69%

Institutional and Insider Ownership

6.2% of GenVec shares are held by institutional investors. Comparatively, 42.9% of CTI BioPharma Corp. shares are held by institutional investors. 8.1% of GenVec shares are held by company insiders. Comparatively, 8.1% of CTI BioPharma Corp. shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Volatility and Risk

GenVec has a beta of 3.34, suggesting that its stock price is 234% more volatile than the S&P 500. Comparatively, CTI BioPharma Corp. has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500.

Summary

CTI BioPharma Corp. beats GenVec on 9 of the 11 factors compared between the two stocks.

GenVec Company Profile

GenVec, Inc. (GenVec) is a clinical-stage biopharmaceutical company, engaged in the development of therapeutics and vaccines. The Company designs, tests and manufactures adenoviral-based product candidates. The Company’s development programs address therapeutic areas, such as hearing loss and balance disorders, as well as vaccines against infectious diseases, including respiratory syncytial virus (RSV), herpes simplex virus (HSV), Enterovirus D68 (EV-D68) and malaria. In the area of animal health, it is developing vaccines against foot-and-mouth disease (FMD). The Company develops and commercializes its product candidates through collaborations. The Company’s lead product candidate is CGF166. The Company’s vaccine candidates include preventative vaccines against RSV and malaria, and a therapeutic vaccine for HSV. The Company is developing vaccine and anti-viral candidates for the prevention and containment of FMD outbreaks.

CTI BioPharma Corp. Company Profile

CTI BioPharma Corp. (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). It is also engaged in evaluating pacritinib for the treatment of adult patients with myelofibrosis. Its earlier stage product candidate, tosedostat, is an oral, once-daily aminopeptidase inhibitor that has demonstrated responses in patients with acute myeloid leukemia (AML). It also evaluates its pipeline candidate paclitaxel poliglumex (Opaxio), which targets solid tumors. It is evaluating Opaxio through cooperative group sponsored trials and investigator-sponsored trials (ISTs), such as the ongoing maintenance therapy trial in patients with ovarian cancer.

Receive News & Ratings for GenVec Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenVec Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply